Bleomycin/cisplatin/etoposide

Bleomycin/cisplatin/etoposide Reactions 1704, p72 - 2 Jun 2018 Thrombocytopenia and anaemia: 2 case reports In a single center retrospective study involving 18 female patients, two female patients [ages not stated] were described, who developed thrombocytopenia (1 female patient) and anaemia (1 female patient) during treatment with bleomycin, cisplatin and etoposide for advanced yolk sac tumour [routes, duration of treatments to reaction onsets and outcomes not stated]. The female patients, who had inoperable advanced yolk sac tumour, started receiving neoadjuvant chemotherapy with bleomycin, cisplatin and etoposide. Bleomycin was administered at a dose of 15 mg/m per day on days 1 3, etoposide at a dose of 80 mg/m per day on days 1 5 and cisplatin at a dose of 20 mg/m per day on days 1 5. The female patients, who desired to preserve their fertility, were scheduled to undergo fertility-sparing surgery upon completion of the neoadjuvant chemotherapy. The cycles were repeated every 21 days. However, while receiving the neoadjuvant chemotherapy, one female patient developed grade 3-4 thrombocytopenia and another female patient developed grade 3 anaemia. The patient with thrombocytopenia required platelet transfusion. Author comment: "Grades 3 4 thrombocytopenia was observed in 3 cases, and platelet transfusion was indicated for 1 patient. Grade 3 anemia was observed in 1 patient." Zhang G-Y, et al. Neoadjuvant Bleomycin, Etoposide, and Cisplatin (BEP) Chemotherapy in the Treatment of Extensively Advanced Yolk Sac Tumors: A Single Center Experience. International Journal of Gynecological Cancer 28: 713-720, No. 4, May 2018. Available from: URL: http://doi.org/10.1097/ IGC.0000000000001209 - China 803323940 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Bleomycin/cisplatin/etoposide

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/bleomycin-cisplatin-etoposide-WfHdmd5OHR
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46715-9
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p72 - 2 Jun 2018 Thrombocytopenia and anaemia: 2 case reports In a single center retrospective study involving 18 female patients, two female patients [ages not stated] were described, who developed thrombocytopenia (1 female patient) and anaemia (1 female patient) during treatment with bleomycin, cisplatin and etoposide for advanced yolk sac tumour [routes, duration of treatments to reaction onsets and outcomes not stated]. The female patients, who had inoperable advanced yolk sac tumour, started receiving neoadjuvant chemotherapy with bleomycin, cisplatin and etoposide. Bleomycin was administered at a dose of 15 mg/m per day on days 1 3, etoposide at a dose of 80 mg/m per day on days 1 5 and cisplatin at a dose of 20 mg/m per day on days 1 5. The female patients, who desired to preserve their fertility, were scheduled to undergo fertility-sparing surgery upon completion of the neoadjuvant chemotherapy. The cycles were repeated every 21 days. However, while receiving the neoadjuvant chemotherapy, one female patient developed grade 3-4 thrombocytopenia and another female patient developed grade 3 anaemia. The patient with thrombocytopenia required platelet transfusion. Author comment: "Grades 3 4 thrombocytopenia was observed in 3 cases, and platelet transfusion was indicated for 1 patient. Grade 3 anemia was observed in 1 patient." Zhang G-Y, et al. Neoadjuvant Bleomycin, Etoposide, and Cisplatin (BEP) Chemotherapy in the Treatment of Extensively Advanced Yolk Sac Tumors: A Single Center Experience. International Journal of Gynecological Cancer 28: 713-720, No. 4, May 2018. Available from: URL: http://doi.org/10.1097/ IGC.0000000000001209 - China 803323940 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off